Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

August 31, 2026

- Chloe Kim is partnering with Supernus to highlight the importance of recognizing ADHD in adults and help empower individuals to work with their doctors to develop a tailored treatment plan.
- While ADHD is often associated with childhood, symptoms frequently persist into adulthood, and many people go undiagnosed until later in life.[1]
- Supported by years of clinical and real-world experience, Qelbree offers an established, non-controlled treatment option with approximately 3 million total prescriptions filled since launch in 2021.

ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day routine integration, Qelbree offers 24-hour medication exposure, no evidence of abuse potential, and versatile administration options, including the ability to be sprinkled and taken at any time of day (either morning or night). Through this partnership, Chloe Kim will open up about her own diagnosis to challenge misconceptions about ADHD. By sharing her lived experience, she will encourage others to advocate for their health and initiate collaborative conversations with their doctors about a potential treatment plan.

“Teaming up with Supernus to share my personal experience with ADHD is about turning my diagnosis into advocacy,” said Kim. This partnership comes following the recent five-year anniversary of the U.S. Food and Drug Administration (FDA) approval of Qelbree for ADHD. As of May 2026, Qelbree is the #1 prescribed branded non-stimulant ADHD medication and has been widely used in real-world clinical practice since approval.

“Our focus remains on listening to and learning from real patient stories to help address personalized needs, since no two people experience ADHD in the exact same way,” said Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We’re thrilled to join forces with Chloe Kim to spark honest conversations and share new perspectives that may help others feel understood and see themselves in her story.”

For more information about Qelbree, visit www.qelbree.com. Patients should speak to a doctor about all the medications they take and to see if Qelbree could be right for them.

*As of May 2026

INDICATION

Qelbree® (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in adults and children 6 years and older.

IMPORTANT SAFETY INFORMATION

Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

You or your child should not take Qelbree if you or your child:
Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your or your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania.

Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired.

The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed Warning, and Medication Guide for Qelbree here.

Qelbree (viloxazine extended-release capsules) is available in 100 mg, 150 mg and 200 mg capsules.

About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous

system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.

For more information, please visit www.supernus.com.

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; the Company's ability to increase its net revenue from its products, and the products of its subsidiaries; the Company's ability to commercialize its products, and the products of its subsidiaries; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

1. Centers for Disease Control and Prevention (CDC). ADHD in Adults: An Overview. June 1, 2026. https://www.cdc.gov/adhd/articles/adhd-across-the-lifetime.html

CONTACTS:

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591

Or

INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com

Or

MEDIA CONTACT:
Rebecca Finck
Burson
(646) 358-7675
rebecca.finck@bursonglobal.com

QBE.2026-0226